[18F]F-FAPI PET/CT 在肺癌淋巴结分期中优于 [18F]F-FDG PET/CT:一项病理验证研究
本研究以病理为参考标准,比较 [18F]F-FAPI 与 [18F]F-FDG PET/CT 对肺癌淋巴结分期的诊断效能。32 例 FDG 阳性淋巴结患者接受 [18F]F-FAPI PET/CT,71 枚淋巴结经手术或 EBUS-TBNA 病理确认(23 枚转移、48 枚良性)。结果显示 FAPI 的 AUC、特异度和准确性均显著高于 FDG,淋巴结分期准确率为 93.8% 对 43.8%,并可使部分 EBUS-TBNA 安全避免。
要点
- 转移淋巴结 FAPI SUVmax 为 13.6±9.6,显著高于良性淋巴结的 2.7±1.9(p<0.001)。
- FAPI 的 AUC 为 0.98(95%CI 0.95-1.0),显著高于 FDG 的 0.78(0.65-0.89)(p<0.001)。
- SUVmax>5.3 时 FAPI 可正确识别全部 23 枚转移淋巴结,假阳性率 0% 对 FDG 的 83.3%。
核心结论
- [18F]F-FAPI PET/CT 是肺癌淋巴结分期的有前景工具,特异度更高、假阳性更少,有望优化侵入性分期流程。
研究设计与样本
- 32 例 FDG 阳性淋巴结的肺癌患者接受 [18F]F-FAPI PET/CT,71 枚淋巴结经手术或 EBUS-TBNA 病理确认(23 枚转移、48 枚良性)。
- 基于淋巴结和基于患者计算 SUVmax、TBR、灵敏度、特异度、准确性、PPV 和 NPV,并以 ROC 曲线比较 FAPI 与 FDG。
主要发现
- 转移淋巴结 FAPI 摄取显著高于良性淋巴结,SUVmax 分别为 13.6±9.6 与 2.7±1.9(p<0.001)。
- FAPI 的 AUC 为 0.98(95%CI 0.95-1.0),FDG 为 0.78(0.65-0.89),差异有统计学意义(p<0.001)。
- FAPI 与 FDG 的灵敏度均为 100%,特异度 91.7% 对 16.7%,准确性 97.0% 对 43.9%,PPV 85.2% 对 36.5%,NPV 均为 100%。
- SUVmax 切点>5.3 时,FAPI 正确识别全部 23 枚转移淋巴结,假阳性率 0% 对 FDG 的 83.3%。
- FAPI 淋巴结分期准确率 93.8%(30/32)高于 FDG 的 43.8%(14/32),使 15 例患者降期;42.9%(9/21)接受 EBUS-TBNA 的患者该操作可安全避免。
关键数值与推荐
- SUVmax 切点>5.3 时,[18F]F-FAPI 可正确识别全部 23 枚转移淋巴结,假阳性率 0%。
临床怎么用
- 对 FDG 阳性淋巴结的肺癌患者,FAPI PET/CT 可提高淋巴结分期特异性、减少假阳性,并可能减少不必要的 EBUS-TBNA。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Accurate lymph node staging in lung cancer remains challenging. This study evaluates the diagnostic efficacy of fibroblast activation protein inhibitor (FAPI) versus fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) using histopathology as the reference standard. METHODS: Thirty-two lung cancer patients with FDG-positive lymph nodes underwent [¹⁸F]F-FAPI PET/CT. Pathological confirmation of 71 lymph nodes (23 metastatic, 48 benign) was obtained via surgery or endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). Diagnostic efficacy was evaluated on both lymph node-based and patient-based, including maximum standardized uptake value (SUVmax), tumor-to-background ratio (TBR), sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) . RESULTS: Metastatic lymph nodes showed significantly higher FAPI uptake vs. benign lymph nodes [SUVmax: (13.6 ± 9.6) vs. (2.7 ± 1.9)]; p < 0.001). Receiver operating characteristic (ROC) analysis showed a significantly larger area under the curve (AUC) for [18F]F-FAPI compared to [18F]F-FDG [AUC 0.98 (95% CI 0.95-1.0) vs. AUC 0.78 (0.65-0.89), (p < 0.001)]. In this cohort of patients with FDG-positive lymph nodes, [18F]F-FAPI presented greater lymph node detection sensitivity, specificity, accuracy, PPV and NPV than [18F]F-FDG (100% vs. 100%, 91.7% vs. 16.7%, 97.0% vs. 43.9%, 85.2% vs. 36.5% and 100% vs. 100% respectively). When the cut-off value of SUVmax is greater than 5.3, [18F]F-FAPI can correctly identify all 23 metastatic lymph nodes with much lower false positive rate than [18F]F-FDG (0% vs. 83.3%). [18F]F-FAPI shows higher lymph node staging accuracy than [18F]F-FDG [93.8% (30/32) vs. 43.8% (14/32)], led to downstaging in 15 patients. In 42.9% (9/21) of patients who underwent EBUS-TBNA, the procedure could have been safely avoided. CONCLUSION: [18F]F-FAPI PET/CT is a promising tool for lymph node staging of lung cancer, offering higher specificity and reduced false positives, with potential to optimize invasive staging procedures.
引用
- Jiang J, Li B, Mao J, et al. [18F]F-FAPI PET/CT is superior to [18F]F-FDG PET/CT for lymph node staging in lung cancer: a pathologically validated study. Eur J Nucl Med Mol Imaging. 2026. PMID: 42142270. doi:10.1007/s00259-026-07930-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。